Clinical outcome and adherence rate in Scandinavian patients with intermediate‐intensity prophylaxis before and after the switch of standard half‐life FVIII products to BAY 81

Clinical outcome and adherence rate in Scandinavian patients with intermediate‐intensity prophylaxis before and after the switch of standard half‐life FVIII products to BAY 81–8973

Published:2022-01-10 Issue:2 Volume:28 Page:223-229
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Arvanitakis Alexandros¹²^ORCID,Holme Pål Andre³⁴,Berntorp Erik¹^ORCID,Astermark Jan¹²^ORCID

Affiliation:

1. Department of Translational Medicine Lund University Malmö Sweden

2. Department of Haematology Oncology and Radiation Physics Skåne University Hospital Malmö Sweden

3. Department of Haematology Oslo University Hospital Oslo Norway

4. Institute of Clinical Medicine University of Oslo Oslo Norway

Publisher

Wiley

Subject

Genetics (clinical),Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.14489

Reference33 articles.

1. Modern haemophilia care

2. Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized

3. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B

4. Anti‐hemophilic factor (recombinant), plasma/albumin‐free method (octocog‐alpha; ADVATE) in the management of hemophilia A;Shapiro AD;Vasc Health Risk Manage,2007

5. Evolution of recombinant factor VIII safety: KOGENATE® and Kogenate® FS/Bayer

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Classification of recombinant factor VIII products and implications for clinical practice: A systematic literature review;Haemophilia;2024-03-29

2. Impact of timing of prophylaxis commencement, F8 genotype and age on factor consumption and health‐related quality of life in patients with severe haemophilia A;Haemophilia;2023-05-30